363 related articles for article (PubMed ID: 28768964)
1. The Risk Factors for the Wearing-off Phenomenon in Parkinson's Disease in Japan: A Cross-sectional, Multicenter Study.
Ouma S; Fukae J; Fujioka S; Yamamoto S; Hatano T; Yoritaka A; Okuma Y; Kashihara KI; Hattori N; Tsuboi Y
Intern Med; 2017; 56(15):1961-1966. PubMed ID: 28768964
[TBL] [Abstract][Full Text] [Related]
2. Opicapone to Treat Early Wearing-off in Parkinson's Disease Patients: The Korean ADOPTION Trial.
Lee JY; Ma HI; Ferreira JJ; Rocha JF; Sung YH; Song IU; Ahn TB; Kwon DY; Cheon SM; Kim JM; Lee CS; Lee PH; Park JH; Lee JH; Park MY; Kim SJ; Baik JS; Choi SM; Shin HW; Lee HW; Kang SY; Jeon B
Mov Disord Clin Pract; 2024 Jun; 11(6):655-665. PubMed ID: 38594812
[TBL] [Abstract][Full Text] [Related]
3. Risk factors and safe dosage of levodopa for wearing-off phenomenon in Chinese patients with Parkinson's disease.
Chen H; Fang J; Li F; Gao L; Feng T
Neurol Sci; 2015 Jul; 36(7):1217-23. PubMed ID: 25616444
[TBL] [Abstract][Full Text] [Related]
4. Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson's disease.
Ferreira JJ; Rocha JF; Falcão A; Santos A; Pinto R; Nunes T; Soares-da-Silva P
Eur J Neurol; 2015 May; 22(5):815-25, e56. PubMed ID: 25649051
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off.
Kuoppamäki M; Leinonen M; Poewe W
J Neural Transm (Vienna); 2015 Dec; 122(12):1709-14. PubMed ID: 26347184
[TBL] [Abstract][Full Text] [Related]
6. Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease.
Yamamoto M; Yokochi M; Kuno S; Hattori Y; Tsukamoto Y; Narabayashi H; Tohgi H; Mizuno Y; Kowa H; Yanagisawa N; Kanazawa I
J Neural Transm (Vienna); 1997; 104(2-3):229-36. PubMed ID: 9203084
[TBL] [Abstract][Full Text] [Related]
7. Utility of the Japanese version of the 9-item Wearing-off Questionnaire.
Fukae J; Higuchi MA; Yanamoto S; Fukuhara K; Tsugawa J; Ouma S; Hatano T; Yoritaka A; Okuma Y; Kashihara K; Hattori N; Tsuboi Y
Clin Neurol Neurosurg; 2015 Jul; 134():110-5. PubMed ID: 25985062
[TBL] [Abstract][Full Text] [Related]
8. Advanced Parkinson's disease treatment patterns in Italy: an observational study interim analysis.
Stocchi F; Barone P; Ceravolo R; De Pandis MF; Lopiano L; Modugno N; Padovani A; Pilleri M; Tessitore A; Zappia M
Ann Med; 2024 Dec; 56(1):2315226. PubMed ID: 38381654
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for developing dyskinesia among Parkinson's disease patients with wearing-off: J-FIRST.
Mishima T; Chiu SW; Saiki H; Yamaguchi T; Shimo Y; Maeda T; Watanabe H; Kashihara K; Nomoto M; Hattori N; Tsuboi Y;
J Neurol Sci; 2023 May; 448():120619. PubMed ID: 37023638
[TBL] [Abstract][Full Text] [Related]
10. Motor and non-motor wearing-off and its impact in the quality of life of patients with Parkinson's disease.
Rodríguez-Violante M; Ospina-García N; Dávila-Avila NM; Cruz-Fino D; Cruz-Landero A; Cervantes-Arriaga A
Arq Neuropsiquiatr; 2018 Aug; 76(8):517-521. PubMed ID: 30231124
[TBL] [Abstract][Full Text] [Related]
11. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease.
Warren Olanow C; Kieburtz K; Rascol O; Poewe W; Schapira AH; Emre M; Nissinen H; Leinonen M; Stocchi F;
Mov Disord; 2013 Jul; 28(8):1064-71. PubMed ID: 23630119
[TBL] [Abstract][Full Text] [Related]
12. Cardiac Sympathetic Denervation Can Predict the Wearing-off Phenomenon in Patients with Parkinson Disease.
Lee JE; Kim JS; Ryu DW; Oh YS; Yoo IR; Lee KS
J Nucl Med; 2018 Nov; 59(11):1728-1733. PubMed ID: 29572255
[TBL] [Abstract][Full Text] [Related]
13. Safinamide as adjunctive therapy to levodopa monotherapy for patients with Parkinson's disease with wearing-off: The Japanese observational J-SILVER study.
Nishikawa N; Hatano T; Nishioka K; Ueno SI; Saiki S; Nakamura R; Yoritaka A; Ogawa T; Shimo Y; Sako W; Shimura H; Furukawa Y; Kamei T; Ishida T; Hattori N;
J Neurol Sci; 2024 Jun; 461():123051. PubMed ID: 38788287
[TBL] [Abstract][Full Text] [Related]
14. Combining entacapone with levodopa/DDCI improves clinical status and quality of life in Parkinson's Disease (PD) patients experiencing wearing-off, regardless of the dosing frequency: results of a large multicentre open-label study.
Onofrj M; Thomas A; Vingerhoets F; Martin W; Giménez-Roldán S; Azulay JP; Bernhard G; Schmidt W; Markabi S
J Neural Transm (Vienna); 2004 Aug; 111(8):1053-63. PubMed ID: 15254793
[TBL] [Abstract][Full Text] [Related]
15. Role of the pharmacist in the effective management of wearing-off in Parkinson's disease.
Simonson W; Hauser RA; Schapira AH
Ann Pharmacother; 2007 Nov; 41(11):1842-9. PubMed ID: 17878397
[TBL] [Abstract][Full Text] [Related]
16. Levodopa-related wearing-off in Parkinson's disease: identification and management.
Pahwa R; Lyons KE
Curr Med Res Opin; 2009 Apr; 25(4):841-9. PubMed ID: 19228103
[TBL] [Abstract][Full Text] [Related]
17. A 12-month prospective real-life study of opicapone efficacy and tolerability in Emirati and non-White subjects with Parkinson's disease based in United Arab Emirates.
Metta V; Ibrahim H; Muralidharan N; Rodriguez K; Masagnay T; Mohan J; Lacsina A; Ahmed A; Benamer HTS; Chung-Faye G; Mrudula R; Falup-Pecurariu C; Rodriguez-Blazquez C; Borgohain R; Goyal V; Bhattacharya K; Chaudhuri KR
J Neural Transm (Vienna); 2024 Jan; 131(1):25-30. PubMed ID: 37798410
[TBL] [Abstract][Full Text] [Related]
18. MAO-B and COMT Genetic Variations Associated With Levodopa Treatment Response in Patients With Parkinson's Disease.
Sampaio TF; Dos Santos EUD; de Lima GDC; Dos Anjos RSG; da Silva RC; Asano AGC; Asano NMJ; Crovella S; de Souza PRE
J Clin Pharmacol; 2018 Jul; 58(7):920-926. PubMed ID: 29578580
[TBL] [Abstract][Full Text] [Related]
19. Prevalence and associated features of self-reported freezing of gait in Parkinson disease: The DEEP FOG study.
Amboni M; Stocchi F; Abbruzzese G; Morgante L; Onofrj M; Ruggieri S; Tinazzi M; Zappia M; Attar M; Colombo D; Simoni L; Ori A; Barone P; Antonini A;
Parkinsonism Relat Disord; 2015 Jun; 21(6):644-9. PubMed ID: 25899545
[TBL] [Abstract][Full Text] [Related]
20. Abdominal pain: a symptom of levodopa end of dose wearing off in Parkinson's disease.
Rana AQ; Depradine J
West Indian Med J; 2011 Mar; 60(2):223-4. PubMed ID: 21942133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
